Lara Dunn, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Badri Modi, MD
Assistant Clinical Professor, Division of Dermatology
Department of Surgery
City of Hope Comprehensive Cancer Center
Christie Avraamides, PhD
Clinical Content Manager
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Samantha Gordon, MS
Director of CME
Edward Allan Racela Sison, MD
Missouri City, TX
Upon completion, participants should be able to:
This activity is intended for dermatologists.
Statement of Need
In the United States (US), an estimated 1 million individuals are affected by CSCC each year. Although locoregional or distant metastatic disease occurs in only 1% to 5% of cases, mortality in these individuals is high. Several clinical and pathologic features correlate with an increased risk of tumor recurrence and metastasis; however, there is a lack of agreement over the definition of high-risk CSCC. Therefore, a greater understanding of the CSCC features associated with poor prognosis is needed among dermatologists. In terms of treatment, surgical management is the most effective for CSCC, and the majority of CSCC cases are amenable to surgery alone. However, 10% of cases progress to advanced CSCC. Recently, 2 immunotherapies were approved by the US Food and Drug Administration for advanced CSCC, which has practice-changing implications across the clinical disciplines that diagnose, assess, and treat patients with advanced/malignant CSCC. Dermatologists must be able to identify appropriate patients for excision in a dermatology office, referral for surgical evaluation, and referral to a medical oncologist for evaluation for systemic therapy.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points from the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number. Please note, your name, ABIM ID number, birthdate and completion status will be shared with ABIM through the ACCME PARS system. Your points will be automatically submitted to the ABIM on your behalf; please allow 4 weeks for your points to display on the ABIM website.
Medium/Method of Participation
This is a 0.75-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: 1/29/2021
Expiration Date: 1/28/2022
Estimated Time to Complete This Activity: 45 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Lara Dunn, MD
Consulting fees/advisory boards: Merck & Co., Inc., Regeneron Pharmaceuticals, Inc.
Contracted research: Cue Biopharma, Eisai Inc., Regeneron Pharmaceuticals, Inc.
Badri Modi, MD
Consulting fees/advisory boards: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Fees received for promotional/non-CME activities: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Edward Allan Racela Sison, MD
Salary: Covance, Inc., LabCorp, Precision Medical Group
Ownership interest (stocks/stock options – excluding mutual funds): LabCorp, Precision Medical Group, United HealthCare
The peer reviewers and other activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Applications & Software
For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
© 2021 Med-IQ, Inc.
Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.
Click “Continue” to proceed through this activity and receive credit, or select a specific module from the menu on the left.